Emulate Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
76
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$10M
- Investors
-
32
Emulate General Information
Description
Developer of organ-on-a-chip technology designed to predict human response with greater precision and detail than other experimental testing methods. The company's human emulation system provides a window into the inner workings of human biology and disease, offering researchers an innovative technology that conventional cell culture or animal-based experimental testing, enabling doctors to get detailed insights into the human body and its cells.
Contact Information
Website
www.emulatebio.comCorporate Office
- 27 Drydock Avenue
- 5th floor
- Boston, MA 02210
- United States
Corporate Office
- 27 Drydock Avenue
- 5th floor
- Boston, MA 02210
- United States
Emulate Timeline
Emulate Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Later Stage VC (Series C) | 28-Oct-2025 | $10M | Completed | Generating Revenue | ||
| 11. Grant | 21-May-2024 | Completed | Generating Revenue | |||
| 10. Later Stage VC (Series F) | 20-Mar-2024 | Completed | Generating Revenue | |||
| 9. Later Stage VC (Series E) | 23-Aug-2021 | Completed | Generating Revenue | |||
| 8. Grant | 31-Dec-2020 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series D) | 23-Mar-2020 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series C) | 19-Jun-2018 | Completed | Generating Revenue | |||
| 5. Grant | 20-Jun-2017 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series B) | 20-Oct-2016 | $45M | $57M | Completed | Generating Revenue | |
| 3. Early Stage VC (Series A) | 11-Jul-2014 | $12M | $12M | Completed | Generating Revenue |
Emulate Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series F-1 | ||||||||
| Series F-3 | ||||||||
| Series F-2 | ||||||||
| Series E-2 | ||||||||
| Series E-1 | ||||||||
| Series D | ||||||||
| Series C | ||||||||
| Series B | 18,000,000 | $0.000100 | 6% | $25 | $25 | 1x | $6.3 | 59.48% |
| Series A | 18,000,000 | $0.000100 | 6% | $10 | $10 | 1x | $3.07 | 48.84% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Emulate Comparisons
Industry
Financing
Details
Emulate Competitors (8)
One of Emulate’s 8 competitors is Stemnovate, a Venture Capital-Backed company based in Cambridge, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Stemnovate | Venture Capital-Backed | Cambridge, United Kingdom | ||||
| 28bio | Venture Capital-Backed | New Orleans, LA | ||||
| MIMETAS | Venture Capital-Backed | Oegstgeest, Netherlands | ||||
| Ncardia | Venture Capital-Backed | Leiden, Netherlands | ||||
| CN-Bio | Venture Capital-Backed | Cambridge, United Kingdom |
Emulate Patents
Emulate Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240082795-A1 | Dispensing machine | Pending | 08-Sep-2022 | ||
| AU-2020388676-A1 | Antibody producing microfluidic devices | Active | 21-Nov-2019 | ||
| AU-2020388676-B2 | Antibody producing microfluidic devices | Inactive | 21-Nov-2019 | ||
| CA-3158045-A1 | Antibody producing microfluidic devices | Pending | 21-Nov-2019 | ||
| GB-202208044-D0 | Antibody producing microfluidic devices | Active | 21-Nov-2019 | C07K16/00 |
Emulate Signals
Emulate Investors (32)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Lush. | Corporation | |||
| Qiming Venture Partners | Venture Capital | Minority | ||
| United States Department of War | Government | |||
| Alumni Ventures | Venture Capital | Minority | ||
| Alwyn Capital | Venture Capital | Minority |
Emulate FAQs
-
When was Emulate founded?
Emulate was founded in 2013.
-
Where is Emulate headquartered?
Emulate is headquartered in Boston, MA.
-
What is the size of Emulate?
Emulate has 76 total employees.
-
What industry is Emulate in?
Emulate’s primary industry is Biotechnology.
-
Is Emulate a private or public company?
Emulate is a Private company.
-
What is Emulate’s current revenue?
The current revenue for Emulate is .
-
How much funding has Emulate raised over time?
Emulate has raised $278M.
-
Who are Emulate’s investors?
Lush., Qiming Venture Partners, United States Department of War, Alumni Ventures, and Alwyn Capital are 5 of 32 investors who have invested in Emulate.
-
Who are Emulate’s competitors?
Stemnovate, 28bio, MIMETAS, Ncardia, and CN-Bio are some of the 8 competitors of Emulate.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process